Search
Welcome to the EHA2025 Sponsor Program
On this page, you can browse and/or download the interactive EHA2025 Sponsor Program. If the EHA2025 Sponsor Program does not display correctly, please click here or download the file.
Read moreEHA Research Grants
The call for applications is closed. EHA Research Grants support talented junior researchers in advancing their career—for example, by helping them move towards becoming the leader of a research group.
Read moreEvidence and policy to ensure good clinical practice
Interview with Vinay Prasad MD MPH by Heiko Becker MD, on behalf of YoungEHA
Leaders in the field that have the potential to make a difference, that challenge the way we are doing things, who push our perspective out of our…
Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years
ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.
Read moreCall for interest
As a member of an EHA committee or taskforce, you’ll be instrumental in taking our ambitions to the next level.
Read more